文献速递临床试验与 GCP流行病学与生物统计

临床试验安慰剂组中反安慰剂效应的系统综述快速概览

Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials.
PubMed 文献 · Trials · 2018-12-11

该研究通过检索PubMed并手工筛选,纳入20篇系统综述(含1271项随机试验、250726例安慰剂组患者),发现安慰剂组不良事件中位发生率为49.1%(IQR 25.7-64.4%),因不良事件退出率中位数为5%(IQR 2.28-8.4%)。在15项报告未治疗组不良事件的试验中,安慰剂组不良事件率(6.51%)高于未治疗组(4.25%)。结论认为安慰剂组不良事件常见,不能完全归因于疾病自然史。

要点

  • 安慰剂组不良事件中位发生率49.1%,因不良事件退出率中位数5%。
  • 安慰剂组不良事件率(6.51%)高于未治疗组(4.25%)。
  • 需开发既满足知情同意又减少安慰剂组不良事件的试验方法。

核心结论

  • 安慰剂组不良事件常见,不能完全归因于疾病自然史。
  • 应开发并实施减少安慰剂组不良事件且满足知情同意要求的试验方法。

研究设计与样本

  • 系统综述的快速概览,检索PubMed中标题含nocebo且任意字段含systematic的记录,并联系专家和手工检索参考文献。
  • 纳入20篇系统综述,涵盖1271项随机试验和250726例安慰剂组患者,使用缩短版AMSTAR工具评价质量。
  • 报告不良事件的中位数和四分位距(IQR),并在包含未治疗组的试验中比较未治疗组与安慰剂组的不良事件发生率。

主要发现

  • 安慰剂组不良事件中位发生率为49.1%(IQR 25.7-64.4%)。
  • 因不良事件退出率中位数为5%(IQR 2.28-8.4%)。
  • 在15项报告未治疗组不良事件的试验中,安慰剂组不良事件率(6.51%)高于未治疗组(4.25%)。

临床怎么用

  • 临床解读安慰剂组不良事件时需考虑反安慰剂效应,不能全部归因于疾病本身。
  • 试验设计应关注减少安慰剂组不良事件的策略,同时满足知情同意要求。

局限性

  • 受纳入综述质量限制。
  • 包含未治疗组的试验数量较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trial participants in placebo groups report experiencing adverse events (AEs). Existing systematic reviews have not been synthesized, leaving questions about why these events occur as well as their prevalence across different conditions unanswered. OBJECTIVES: (1) To synthesize the evidence of prevalence of AEs in trial placebo groups across different conditions. (2) To compare AEs in trial placebo groups with AEs reported in untreated groups within a subset of randomized trials. SEARCH METHODS: We searched PubMed for records with the word "nocebo" in the title and "systematic" in any field. We also contacted experts and hand-searched references of included studies. STUDY ELIGIBILITY: We included any systematic review of randomized trials where nocebo effects were reported. We excluded systematic reviews of non-randomized studies. PARTICIPANTS AND INTERVENTIONS: We included studies in any disease area. STUDY APPRAISAL AND SYNTHESIS METHODS: We appraised the quality of the studies using a shortened version of the Assessment of Multiple Systematic Reviews tool (AMSTAR) tool. We reported medians and interquartile ranges (IQRs) of AEs. Among the trials within the review that included untreated groups, we compared the prevalence of AEs in untreated groups with the prevalence of AEs in placebo groups. RESULTS: We identified 20 systematic reviews. These included 1271 randomized trials and 250,726 placebo-treated patients. The median prevalence of AEs in trial placebo groups was 49.1% (IQR 25.7-64.4%). The median rate of dropouts due to AEs was 5% (IQR 2.28-8.4%). Within the 15 of trials that reported AEs in untreated groups, we found that the AE rate in placebo groups (6.51%) was higher than that reported in untreated groups (4.25%). LIMITATIONS: This study was limited by the quality of included reviews and the small number of trials that included untreated groups. CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS: AEs in trial placebo groups are common and cannot be attributed entirely to natural history. Trial methodologies that reduce AEs in placebo groups while satisfying the requirement of informed consent should be developed and implemented.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Howick J, Webster R, Kirby N, et al. Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials. Trials. 2018. PMID: 30526685. doi:10.1186/s13063-018-3042-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。